2,451 results match your criteria Current Opinion in Lipidology[Journal]


The biochemical and genetic diagnosis of lipid disorders.

Curr Opin Lipidol 2019 Jan 31. Epub 2019 Jan 31.

Eurofins Genomics, Louisville, Kentucky, USA.

Purpose Of Review: To examine recent advances in our knowledge on the diagnosis of lipid disorders.

Recent Findings: Fasting values above the 99th percentile for direct LDL-cholesterol (LDL-C), lipoprotein(a), and triglycerides are greater than 225 mg/dl, greater than 160 mg/dl, and greater than 500 mg/dl (>5.82, >394, and >5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000590DOI Listing
January 2019
2 Reads

Recently reported familial hypercholesterolemia-related mutations from cases in the Middle East and North Africa region.

Curr Opin Lipidol 2019 Jan 28. Epub 2019 Jan 28.

Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University.

Purpose Of Review: Familial hypercholesterolemia is an inherited disorder where cases have a significantly higher risk of having premature myocardial infarction than noncases. The prevalence of this genetic disease is currently unknown in countries of the Middle East and North Africa region. Given that a high percentage of marriages are consanguineous in this region, the prevalence may be much higher than assumed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000586DOI Listing
January 2019
1 Read

The evolution of genetic-based risk scores for lipids and cardiovascular disease.

Curr Opin Lipidol 2019 Jan 22. Epub 2019 Jan 22.

Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University.

Purpose Of Review: With improved next-generation sequencing technology, open-access genetic databases and increased awareness of complex trait genetics, we are entering a new era of risk assessment in which genetic-based risk scores (GRSs) will play a clinical role. We review the concepts underlying polygenic models of disease susceptibility and challenges in clinical implementation.

Recent Findings: Polygenic risk scores are currently used in genetic research on dyslipidemias and cardiovascular disease (CVD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000576DOI Listing
January 2019

From HDL-cholesterol to HDL-function: cholesterol efflux capacity determinants.

Curr Opin Lipidol 2019 Jan 21. Epub 2019 Jan 21.

Montreal Heart Institute, Atherosclerosis Research Group.

Purpose Of Review: The validity of HDL-cholesterol (HDL-C) elevation as a therapeutic target has been questioned, in comparison to enhancing HDL functionality. Cholesterol efflux capacity (CEC) is an in-vitro assay that measures the ability of an individual's HDL to promote cholesterol efflux from cholesterol donor cells such as macrophages. CEC of HDL is a predictor of cardiovascular risk independent of HDL-C levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000589DOI Listing
January 2019
8 Reads

Editorial: designing targeted sequencing panels for dyslipidemia.

Authors:
Robert A Hegele

Curr Opin Lipidol 2019 Jan 16. Epub 2019 Jan 16.

Departments of Medicine and Biochemistry, Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000579DOI Listing
January 2019
1 Read

Progress in finding pathogenic DNA copy number variations in dyslipidemia.

Curr Opin Lipidol 2019 Jan 16. Epub 2019 Jan 16.

Robarts Research Institute, and Department of Biochemistry, Schulich School of Medicine and Dentistry.

Purpose Of Review: DNA copy number variations (CNVs) are large-scale mutations that include deletions and duplications larger than 50 bp in size. In the era when single-nucleotide variations were the major focus of genetic technology and research, CNVs were largely overlooked. However, CNVs clearly underlie a substantial proportion of clinical disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000581DOI Listing
January 2019
2 Reads

Pathways of smooth muscle foam cell formation in atherosclerosis.

Curr Opin Lipidol 2019 Jan 16. Epub 2019 Jan 16.

Department of Medicine, Centre for Heart Lung Innovation, Providence Healthcare Research Institute at St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.

Purpose Of Review: Smooth muscle cells (SMCs) are the major cell type in human atherosclerosis-prone arteries and take up excess lipids, thereby contributing to luminal occlusion. Here we provide a focused review on pathways by which smooth muscle cells (SMCs) can become foam cells in atherosclerosis.

Recent Findings: A synthesis of recent and older investigations provides key mechanistic insights into SMC foam cell formation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000574DOI Listing
January 2019
1 Read

Unaccounted risk of cardiovascular disease: the role of the microbiome in lipid metabolism.

Curr Opin Lipidol 2019 Jan 16. Epub 2019 Jan 16.

Department of Biochemistry, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada.

Purpose Of Review: Not all of the risk of cardiovascular disease can be explained by diet and genetics, and the human microbiome, which lies at the interface of these two factors, may help explain some of the unaccounted risk. This review examines some of the well established links between the microbiome and cardiovascular health, and proposes relatively unexplored associations.

Recent Findings: Byproducts of microbial metabolism are associated with health and disease: Trimethylamine N oxide is associated with atherosclerosis; whereas short-chain fatty acids are associated with decreased inflammation and increased energy expenditure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000582DOI Listing
January 2019
2 Reads

Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment.

Curr Opin Lipidol 2019 Jan 14. Epub 2019 Jan 14.

Heart Institute (InCor) University of Sao Paulo Medical School Hospital.

Purpose Of Review: To discuss the heterogeneity of atherosclerotic cardiovascular disease (ASCVD) risk in heterozygous familial hypercholesterolemia and evidence and limitations of clinical risk scores and subclinical coronary atherosclerosis (SCA) imaging to evaluate risk.

Recent Findings: Risk evaluation in contemporary familial hypercholesterolemia cohorts needs to consider the cause of the familial hypercholesterolemia phenotype, for example the presence of autosomal molecular defects that impart a greater ASCVD risk than in polygenic hypercholesterolemia, prospective follow-up and the impact of statin treatment. As atherosclerosis is multifactorial, clinical scores like the Montreal familial hypercholesterolemia score and SAFEHEART risk equation have been proposed to stratify ASCVD in statin-treated, molecularly defined familial hypercholesterolemia individuals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000573DOI Listing
January 2019
7 Reads

Current status of familial hypercholesterolemia in Chinese populations.

Curr Opin Lipidol 2019 Jan 14. Epub 2019 Jan 14.

Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong.

Purpose Of Review: Heterozygous familial hypercholesterolemia often went unrecognized in China when population cholesterol levels were low, but rapid economic development has changed the situation. This review will discuss the current position of awareness, diagnosis, and management of familial hypercholesterolemia in Chinese populations.

Recent Findings: The phenotype of familial hypercholesterolemia in China and other Chinese populations has become similar to that in Western countries, although it may still be somewhat less severe. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000580DOI Listing
January 2019
5 Reads

Cannabis effects on lipoproteins.

Curr Opin Lipidol 2019 Jan 14. Epub 2019 Jan 14.

Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University.

Purpose Of Review: The endocannabinoid system affects several physiological functions. A family of endocannabinoid receptors is susceptible to cannabis constituents. Cannabis is widely used in our society and following its recent legalization in Canada, we focus on how exposure to cannabis and pharmacologic cannabinoid receptor type 1 (CB1) inhibition affect lipoprotein levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000575DOI Listing
January 2019
1 Read

Molecular regulation of plasma lipid levels during systemic inflammation and sepsis.

Curr Opin Lipidol 2019 Jan 14. Epub 2019 Jan 14.

Centre for Heart Lung Innovation.

Purpose Of Review: Sepsis is a common syndrome of multiorgan system dysfunction caused by a dysregulated inflammatory response to an infection and is associated with high rates of mortality. Plasma lipid and lipoprotein levels and composition change profoundly during sepsis and have emerged as both biomarkers and potential therapeutic targets for this condition. The purpose of this article is to review recent progress in the understanding of the molecular regulation of lipid metabolism during sepsis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000577DOI Listing
January 2019
5 Reads

Chylomicron retention disease: genetics, biochemistry, and clinical spectrum.

Curr Opin Lipidol 2019 Jan 11. Epub 2019 Jan 11.

Research Centre.

Purpose Of Review: Chylomicron retention disease (CRD) is an autosomic recessive disorder, in which intestinal fat malabsorption is the main cause of diverse severe manifestations. The specific molecular defect was identified in 2003 and consists of mutations in the SAR1B or SARA2 gene encoding for intracellular SAR1B GTPase protein. The aim of this review is first to provide an update of the recent biochemical, genetic and clinical findings, and second to discuss novel mechanisms related to hallmark symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000578DOI Listing
January 2019
1 Read

Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis.

Curr Opin Lipidol 2019 Feb;30(1):1-9

Department of Biochemistry.

Purpose Of Review: Bempedoic acid has emerged as a potent inhibitor of ATP-citrate lyase (ACLY), a target for the reduction of LDL cholesterol (LDL-C). We review the impact of bempedoic acid treatment on lipoprotein metabolism and atherosclerosis in preclinical models and patients with hypercholesterolemia.

Recent Findings: The liver-specific activation of bempedoic acid inhibits ACLY, a key enzyme linking glucose catabolism to lipogenesis by catalyzing the formation of acetyl-CoA from mitochondrial-derived citrate for de novo synthesis of fatty acids and cholesterol. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00041433-201902000-0000
Publisher Site
http://dx.doi.org/10.1097/MOL.0000000000000565DOI Listing
February 2019
12 Reads

Atherosclerosis: cell biology and lipoproteins.

Curr Opin Lipidol 2019 Feb;30(1):50-52

Department of Clinical Sciences, Skåne University Hospital, Lund University, Malmö, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000562DOI Listing
February 2019
1 Read

An evolutionary look at cholesterol.

Authors:
Uwe J F Tietge

Curr Opin Lipidol 2019 Feb;30(1):48-49

Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000563DOI Listing
February 2019
1 Read

Breastfeeding and cardiovascular risk factors.

Curr Opin Lipidol 2019 Feb;30(1):45-47

Nuffield Department of Population Health, University of Oxford, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000564DOI Listing
February 2019
5 Reads

Lipoprotein metabolism in liver diseases.

Curr Opin Lipidol 2019 Feb;30(1):30-36

Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

Purpose Of Review: The liver is the central hub of lipoprotein metabolism. A complex relationship exists between dyslipidemia and chronic liver diseases (CLDs). Recent advances in the genetics of nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) exemplify the pivotal role of lipoprotein metabolism in the pathogenesis of CLD. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00041433-900000000-9939
Publisher Site
http://dx.doi.org/10.1097/MOL.0000000000000569DOI Listing
February 2019
7 Reads

Effects of apolipoprotein E on nutritional metabolism in dementia.

Curr Opin Lipidol 2019 Feb;30(1):10-15

Geriatric Research, Education, and Clinical Center, Veterans Affairs Puget Sound Healthcare System.

Purpose Of Review: Various groups have explored the effect of apolipoprotein E (APOE) on neurodegeneration through nutritional and metabolic alterations. In this review, we hope to summarize recent findings in humans as well as preclinical APOE models.

Recent Findings: Metabolic pathways including lipid metabolism appear to play a large role in the pathophysiology of Alzheimer's disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000566DOI Listing
February 2019
2 Reads

HDL modification: recent developments and their relevance to atherosclerotic cardiovascular disease.

Curr Opin Lipidol 2019 Feb;30(1):24-29

Departments of Chemistry and Molecular Biosciences and the Proteomics Center of Excellence.

Purpose Of Review: In the last 2 years, significant advances in the understanding of HDL particle structure and the associations between particle structure, function, and atherosclerosis have been made. We will review and provide clinical and epidemiological context to these recent advances.

Recent Findings: Several recent studies have analyzed the associations between HDL particle size distribution, number, and particle function and specific environmental, behavioral, and pharmacologic exposures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000571DOI Listing
February 2019
1 Read

Effects of exercise on HDL functionality.

Curr Opin Lipidol 2019 Feb;30(1):16-23

Department of Exercise Science, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.

Purpose Of Review: Low HDL-cholesterol (HDL-C) levels are a strong predictor of cardiovascular disease risk and can be improved with regular exercise. However, raising HDL-C levels pharmacologically has not shown convincing clinical benefits. Thus, research has recently focused on identifying therapies that improve HDL function, with exercise representing such a potential therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000568DOI Listing
February 2019
1 Read

Dietary fat and risk of type 2 diabetes.

Curr Opin Lipidol 2019 Feb;30(1):37-43

Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf.

Purpose Of Review: Nutrition recommendations emphasize that not only dietary fat quantity but also fat quality plays a role in the prevention of type 2 diabetes (T2D). The aim of this review is to summarize the evidence for dietary fat and risk of T2D, to highlight recent findings and point out future research directions.

Recent Findings: Total fat intake was not associated with risk of T2D, whereas the findings on fatty acids (FAs) and risk of T2D were controversial. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00041433-900000000-9939
Publisher Site
http://dx.doi.org/10.1097/MOL.0000000000000567DOI Listing
February 2019
78 Reads

Emerging roles of HDL in immune function.

Curr Opin Lipidol 2018 Dec;29(6):486-487

Department of Medicine and Pediatrics, Cardiovascular Research Institute, University of California Medical Center, San Francisco, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000555DOI Listing
December 2018
2 Reads

Atherosclerotic cardiovascular disease risk assessment in familial hypercholesterolemia: does one size fit all?

Curr Opin Lipidol 2018 Dec;29(6):445-452

Fundación Hipercolesterolemia Familiar, Madrid, Spain.

Purpose Of Review: Familial hypercholesterolemia is a frequent genetic disease associated with lifelong elevation of LDL-cholesterol and premature atherosclerotic cardiovascular disease (ASCVD). Statins are the cornerstone of treatment. However, with the introduction of novel LDL-cholesterol-lowering therapies, it is necessary to identify familial hypercholesterolemia patients presenting a significantly high residual ASCVD risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000553DOI Listing
December 2018
19 Reads

Mendelian randomization causally link lipoproteins to systemic atherosclerosis and help design clinical trials for the future of lipidology.

Curr Opin Lipidol 2018 Dec;29(6):482-483

Lipid Clinic Heart Institute (InCor), University of Sao Paulo Medical School Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000557DOI Listing
December 2018
1 Read

Writing on the wall for precision medicine in the prevention of atherosclerotic cardiovascular disease.

Curr Opin Lipidol 2018 Dec;29(6):433-435

Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000560DOI Listing
December 2018
1 Read

Colchicine: an affordable anti-inflammatory agent for atherosclerosis.

Curr Opin Lipidol 2018 Dec;29(6):467-473

Harry Perkins Institute of Medical Research.

Purpose Of Review: Inflammation has been shown to be central to the development and progression of atherosclerosis. Despite detailed understanding of its central role and the cellular dynamics, which contribute to atherosclerotic inflammation, there has been slow progress in finding suitable agents to treat it. The recent CANTOS trial showed that the interleukin-1β inhibitor canakinumab can improve outcomes after acute coronary syndromes. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00041433-900000000-9940
Publisher Site
http://dx.doi.org/10.1097/MOL.0000000000000552DOI Listing
December 2018
20 Reads

Intestinal cholesterol absorption.

Curr Opin Lipidol 2018 Dec;29(6):484-485

ANZAC Research Institute.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000558DOI Listing
December 2018
2 Reads

The prediction of therapy-benefit for individual cardiovascular disease prevention: rationale, implications, and implementation.

Curr Opin Lipidol 2018 Dec;29(6):436-444

Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.

Purpose Of Review: We aim to outline the importance and the clinical implications of using predicted individual therapy-benefit in making patient-centered treatment decisions in cardiovascular disease (CVD) prevention. Therapy-benefit concepts will be illustrated with examples of patients undergoing lipid management.

Recent Findings: In both primary and secondary CVD prevention, the degree of variation in individual therapy-benefit is large. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000554DOI Listing
December 2018
4 Reads

RNA-targeted therapeutics for lipid disorders.

Curr Opin Lipidol 2018 Dec;29(6):459-466

Vascular Medicine Program, Sulpizio Cardiovascular Center, Division of Cardiovascular diseases, University of California San Diego School of Medicine, California, USA.

Purpose Of Review: To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

Recent Findings: Despite a number of approved therapies for lipid disorders, significant unmet needs are present in treating persistently elevated LDL-cholesterol, remnant-cholesterol, triglycerides and lipoprotein(a) [Lp(a)]. Small molecules and antibodies are effective modalities, but they are unable to adequately treat many patients with abnormal lipid parameters. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000549DOI Listing
December 2018
2 Reads

Metabolism: The road to inflammation and atherosclerosis.

Curr Opin Lipidol 2018 Dec;29(6):474-480

Department of Experimental Vascular Medicine.

Purpose Of Review: Evidence accumulates suggesting that cellular metabolic alterations fuel and dictate the inflammatory state of cells. In this review, we provide an overview of the observed metabolic reprogramming in endothelial cells and innate immune cells upon interaction with modified lipoproteins, thereby contributing to the progression of atherosclerosis.

Recent Findings: Inflammatory endothelial cells at sites exposed to disturbed flow patterns show increased glycolytic activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000550DOI Listing
December 2018
4 Reads

Key aspects of PCSK9 inhibition beyond LDL lowering.

Curr Opin Lipidol 2018 Dec;29(6):453-458

Purpose Of Review: Our primary objective is to review the most recent findings on the biology of PCSK9 and on two key aspects of PCSK9 inhibition beyond LDL control of great clinical relevance: the regulation of lipoprotein (a) circulating levels by PCSK9 inhibitors and the putative diabetogenic effects of these novel therapies.

Recent Findings: The reality of two distinct extracellular and intracellular pathways by which PCSK9 decreases the abundance of the LDLR at the surface of many cell types, most importantly hepatocytes, has recently been established. In contrast, the exact mechanisms by which PCSK9 inhibitors lower the circulating levels of lipoprotein (a) remain a point of major dispute. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000551DOI Listing
December 2018
2 Reads

Sex differences in metabolism and cardiometabolic disorders.

Curr Opin Lipidol 2018 Oct;29(5):404-410

Department of Medicine/Division of Cardiology.

Purpose Of Review: Sex differences are pervasive in metabolic and cardiovascular traits, yet they have often been ignored in human and animal model research. Sex differences can arise from reversible hormonal effects, from irreversible organizational (developmental) processes, and from gene expression differences from the X and Y chromosomes. We briefly review our current understanding of the impact of these factors in metabolic traits and disorders, with an emphasis on the recent literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000536DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382080PMC
October 2018
1 Read

Lipid-driven immunometabolic responses in atherosclerosis.

Curr Opin Lipidol 2018 Oct;29(5):375-380

Cardiovascular Medicine Unit, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Purpose Of Review: Atherosclerosis is a chronic inflammatory disease in which subendothelial infiltration of lipoproteins leads to inflamed lesions in arteries. Despite improvements in secondary prevention, most cardiovascular events cannot be avoided with current therapies. This review focuses on novel mechanistic insights on lipid-driven immune activation, which could pave the way for new anti-inflammatory treatments for atherosclerosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000540DOI Listing
October 2018
7 Reads

Emerging therapeutic potential of glycine in cardiometabolic diseases: dual benefits in lipid and glucose metabolism.

Curr Opin Lipidol 2018 Oct;29(5):428-432

The Lipid Research Laboratory, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000543DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198663PMC
October 2018
2 Reads

Burning fat to keep your stem cells? The role of fatty acid oxidation in various tissue stem cells.

Curr Opin Lipidol 2018 Oct;29(5):426-427

Department of Physiology, University of Lausanne, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000546DOI Listing
October 2018
3 Reads

Antioxidants and risk of dementia: recent insights and future opportunities.

Curr Opin Lipidol 2018 Oct;29(5):424-425

Department of Nutrition, Harvard T.H. Chan School of Public Health.

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00041433-201810000-0001
Publisher Site
http://dx.doi.org/10.1097/MOL.0000000000000544DOI Listing
October 2018
17 Reads

Fibroblast growth factor-transforming growth factor beta dialogues, endothelial cell to mesenchymal transition, and atherosclerosis.

Curr Opin Lipidol 2018 Oct;29(5):397-403

Yale Cardiovascular Research Center, Department of Internal Medicine.

Purpose Of Review: Despite much effort, atherosclerosis remains an important public health problem, leading to substantial morbidity and mortality worldwide. The purpose of this review is to provide an understanding of the role of endothelial cell fate change in atherosclerosis process.

Recent Findings: Recent studies indicate that a process known as endothelial-to-mesenchymal transition (EndMT) may play an important role in atherosclerosis development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000542DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290915PMC
October 2018
3 Reads

Cardiovascular oncology: exploring the effects of targeted cancer therapies on atherosclerosis.

Curr Opin Lipidol 2018 Oct;29(5):381-388

Department of Medical Biochemistry, Subdivision Experimental Vascular Biology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.

Purpose Of Review: Targeted cancer therapies have revolutionized the treatment of cancer in the past decade, but cardiovascular toxicity is a rising problem in cancer patients. Here we discuss the effects of targeted cancer therapies on atherosclerosis. Increasing the awareness of these adverse effects will promote the development of evidence-based preventive strategies in the emerging field of cardiovascular oncology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000538DOI Listing
October 2018
1 Read

The potential of chronopharmacology for treatment of atherosclerosis.

Curr Opin Lipidol 2018 Oct;29(5):368-374

Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany.

Purpose Of Review: Development of atherosclerosis contributes to cardiovascular diseases that still are the leading cause of mortality worldwide. Successful strategies for treating inflammatory aspects of atherosclerotic lesion development are rare. Here, we review new insights into the impact of circadian rhythmicity on atherogenesis and their potential for innovative time-optimized pharmacological treatment strategies. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00041433-900000000-9941
Publisher Site
http://dx.doi.org/10.1097/MOL.0000000000000545DOI Listing
October 2018
7 Reads

Metabolism of innate immune cells: impact on atherosclerosis.

Curr Opin Lipidol 2018 Oct;29(5):359-367

Department of Internal Medicine, Radboud University Medical Center, Geert Grooteplein Zuid 8, 6525 GA, Nijmegen.

Purpose Of Review: It is increasingly recognized that profound metabolic changes occur in activated myeloid cells, which shape their inflammatory phenotype and cellular functions. The purpose of this review is to summarize the accumulating evidence that major metabolic adaptations occur in monocytes and macrophages in the context of atherosclerosis ultimately modulating atherosclerotic plaque formation.

Recent Findings: Plaque macrophages show a profound metabolic reprogramming which is driven by atherogenic factors in the plaque microenvironment, such as damage associated molecular patterns, modified lipoproteins, and hypoxia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000539DOI Listing
October 2018
2 Reads

Atherosclerosis in the single-cell era.

Curr Opin Lipidol 2018 Oct;29(5):389-396

Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.

Purpose Of Review: The immune system plays a critical role in the development and modulation of atherosclerosis. New high-parameter technologies, including mass cytometry (CyTOF) and single-cell RNA sequencing (scRNAseq), allow for an encompassing analysis of immune cells. Unexplored marker combinations and transcriptomes can define new immune cell subsets and suggest their functions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000537DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314310PMC
October 2018
9 Reads

The many faces of CD8+ T cells in atherosclerosis.

Curr Opin Lipidol 2018 Oct;29(5):411-416

Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.

Purpose Of Review: Atherosclerosis and the clinical consequence of cardiovascular disease remain the leading cause of death worldwide. Both an increase in cholesterol levels, as well as immune responses drive the pathogenesis of this disease. Although much is known about the role of many immune cell subsets in atherogenesis, research into the role of CD8 T cells is limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000541DOI Listing
October 2018
28 Reads

Non-parenchymal hepatic cell lipotoxicity and the coordinated progression of non-alcoholic fatty liver disease and atherosclerosis.

Curr Opin Lipidol 2018 Oct;29(5):417-422

Purpose Of Review: Non-alcoholic fatty liver disease (NAFLD) appears to be independently associated with the development of atherosclerosis. The biological mechanisms underlying this association are complex, and likely involve liver-resident cell types other than hepatocytes. Thus, we review recent evidence that non-parenchymal hepatic cell responses to lipid excess contribute to the pathogenesis of both NAFLD and atherosclerosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000535DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125757PMC
October 2018
3 Reads

Therapy and clinical trials.

Authors:
Klaus G Parhofer

Curr Opin Lipidol 2018 Aug;29(4):357-358

Medizinische Klinik IV-Grosshadern, University Munich, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000531DOI Listing
August 2018
3 Reads

Paths to progress on protective dietary patterns.

Authors:
Dawn C Schwenke

Curr Opin Lipidol 2018 Aug;29(4):355-356

Research Service, VA Northern California Health Care System, Mather, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000530DOI Listing
August 2018
6 Reads

Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?

Curr Opin Lipidol 2018 Aug;29(4):333-339

Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.

Purpose Of Review: Current data suggest that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors may affect many metabolic pathways beyond lowering LDL cholesterol. The aim of the present manuscript is to present these so-called pleiotropic effects of PCSK9 inhibitors.

Recent Findings: PCSK9 may affect the activity of other receptors beyond LDL receptors (LDLR), such as cluster of differentiation 36 (CD36), very-low-density-lipoprotein (VLDL) receptors, apolipoprotein (Apo) E receptors, LDLR-related protein 1 (LRP-1) and ATP-Binding Cassette Transporter (ABCA1). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000523DOI Listing
August 2018
2 Reads

Relevance of human fat distribution on lipid and lipoprotein metabolism and cardiovascular disease risk.

Curr Opin Lipidol 2018 Aug;29(4):285-292

Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital.

Purpose Of Review: Upper body abdominal and lower body gluteofemoral fat depot masses display opposing associations with plasma lipid and lipoprotein and cardiovascular disease (CVD) risk profiles. We review developments on adipose tissue fatty acid metabolism in the context of body fat distribution and how that might be related to adverse lipid and lipoprotein profiles and CVD risk.

Recent Findings: Recent data have confirmed the paradoxical relationship of upper abdominal and lower body gluteofemoral adiposity and CVD risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000522DOI Listing
August 2018
1 Read

Editorial introduction.

Curr Opin Lipidol 2018 Aug;29(4)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000534DOI Listing
August 2018
2 Reads